The crystal structure of PR3, a neutrophil serine proteinase antigen of Wegener's granulomatosis antibodies
about
Discriminating between the activities of human neutrophil elastase and proteinase 3 using serpin-derived fluorogenic substratesWhat you should know about PR3-ANCA. Structural aspects of antibodies to proteinase 3 (PR3).What you should know about PR3-ANCA. Conformational requirements of proteinase 3 (PR3) for enzymatic activity and recognition by PR3-ANCA.New selective peptidyl di(chlorophenyl) phosphonate esters for visualizing and blocking neutrophil proteinase 3 in human diseases.Epitope mapping of anti-PR3 antibodies using chimeric human/mouse PR3 recombinant proteinsX-ray Snapshot of the Mechanism of Inactivation of Human Neutrophil Elastase by 1,2,5-Thiadiazolidin-3-one 1,1-Dioxide Derivatives †Crystal structure of greglin, a novel non-classical Kazal inhibitor, in complex with subtilisinHuman beta-tryptase is a ring-like tetramer with active sites facing a central poreInternalization of proteinase 3 is concomitant with endothelial cell apoptosis and internalization of myeloperoxidase with generation of intracellular oxidantsAnti-neutrophil cytoplasmic antibodies (ANCA) from patients with systemic vasculitis recognize restricted epitopes of proteinase 3 involving the catalytic siteCleavage of p21/WAF1/CIP1 by proteinase 3 modulates differentiation of a monocytic cell line. Molecular analysis of the cleavage site.Kinetics of the inhibition of proteinase 3 by elafin.Structures of human proteinase 3 and neutrophil elastase--so similar yet so different.Utilization of the 1,2,3,5-thiatriazolidin-3-one 1,1-dioxide scaffold in the design of potential inhibitors of human neutrophil proteinase 3.Structural and energetic determinants of the S1-site specificity in serine proteases.Mechanism-based inhibitors of serine proteases with high selectivity through optimization of S' subsite binding.Inhibitors of human neutrophil elastase based on a highly functionalized N-amino-4-imidazolidinone scaffoldEffects of structure on inhibitory activity in a series of mechanism-based inhibitors of human neutrophil elastase.Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.Neutrophil surface presentation of the anti-neutrophil cytoplasmic antibody-antigen proteinase 3 depends on N-terminal processing.Neutrophil serine proteases in antibacterial defense.Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosisB cell epitope specificity in ANCA-associated vasculitis: does it matter?Autoantibodies to intracellular autoantigens and their B-cell epitopes: molecular probes to study the autoimmune response.Inactivation of human neutrophil elastase by 1,2,5-thiadiazolidin-3-one 1,1 dioxide-based sulfonamidesA monoclonal antibody (MCPR3-7) interfering with the activity of proteinase 3 by an allosteric mechanism.Neutrophil proteinase 3 and dipeptidyl peptidase I (cathepsin C) as pharmacological targets in granulomatosis with polyangiitis (Wegener granulomatosis).Inhibitors and Antibody Fragments as Potential Anti-Inflammatory Therapeutics Targeting Neutrophil Proteinase 3 in Human Disease.Molecular analysis of the membrane insertion domain of proteinase 3, the Wegener's autoantigen, in RBL cells: implication for its pathogenic activity.A hydrophobic patch on proteinase 3, the target of autoantibodies in Wegener granulomatosis, mediates membrane binding via NB1 receptors.A proportion of proteinase 3 (PR3)-specific anti-neutrophil cytoplasmic antibodies (ANCA) only react with PR3 after cleavage of its N-terminal activation dipeptide.Cloning and functional expression of the murine homologue of proteinase 3: implications for the design of murine models of vasculitis.Discrimination and variable impact of ANCA binding to different surface epitopes on proteinase 3, the Wegener's autoantigen.Characterization of the CD177 interaction with the ANCA antigen proteinase 3.Heparin accelerates the inhibition of cathepsin G by mucus proteinase inhibitor: potent effect of O-butyrylated heparin.Characterization of human pre-elafin mutants: full antipeptidase activity is essential to preserve lung tissue integrity in experimental emphysema.Oxidized von Willebrand factor is efficiently cleaved by serine proteases from primary granules of leukocytes: divergence from ADAMTS-13.Elastolysis by proteinase 3 and its inhibition by alpha(1)-proteinase inhibitor: a mechanism for the incomplete inhibition of ongoing elastolysis.Compared action of neutrophil proteinase 3 and elastase on model substrates. Favorable effect of S'-P' interactions on proteinase 3 catalysts.Reconstitution of human azurocidin catalytic triad and proteolytic activity by site-directed mutagenesis.
P2860
Q24301375-7C832830-C3F3-4289-BD34-97192E917807Q24791122-76FC1451-0C33-4135-85D7-1CCF7194CCABQ24791178-17AEA31A-3EDC-4DDD-9312-2DEBE5C737DEQ27314812-8FE75F2E-6810-4300-BCCB-AB8A49C047A1Q27478112-DE0390ED-DFD0-47B1-A2D2-7FBC366B861BQ27649985-E80EE7CE-C7BB-414B-91EB-BB8647EF2395Q27682860-E71B7E39-7803-4557-ACA5-600255759015Q27748987-621CDD19-E3FF-4254-8F6B-96FB535F9FFDQ28346162-A9EA3E9C-BD90-459B-946C-A0DAF3C10C52Q28347296-7A7882D9-8673-4005-947E-1DAD43E5824FQ30855520-C995CE56-310F-404B-9A47-848DC42A888BQ31816375-E26F35DD-BCAC-48D4-ACE2-1516E5C997C1Q33348995-9EE42344-3566-48AA-BF1B-FA0A5D17418BQ33522863-ED7B63C4-B28B-4388-9BFA-8750AB4B3F35Q33548213-45E7E0E0-A8DA-4730-86E0-DFC6E3A25D73Q33782834-362CE3ED-23D2-4E69-B43A-671C77AAA36FQ34054400-FA64E155-F501-42FB-9293-FB87062E4143Q34108214-718DBDAA-F42C-4197-A385-F0B9848BEC43Q34149948-11401680-A7DC-4DC2-A752-BC4350C02D60Q34656262-234353F1-DA81-43D1-A18C-6205D152BD95Q35071276-BBA8E114-61C5-46C7-B9B2-06B57E8C67C7Q35241994-E9EEBC8B-87CE-4E69-96F2-B798B5ADB6A0Q35867513-A349F455-F6F5-4BF8-BF48-1CDF5F06BC06Q36436250-ADD86565-7444-4554-B03C-0DF09B721597Q36496641-EE0403F0-F7DD-4F94-83B5-55E49E2E785BQ37168402-FEB7B498-237A-4A76-9009-F759C77EFDE6Q38079492-9D261141-169A-4053-B93B-91D161B0A461Q38850115-D9DAF3FC-F7A0-4608-AB46-6C5796EB4003Q39494029-D68AE466-17A9-4B85-98F7-431AD7345FD4Q39929455-0A55A877-8132-4EDB-992D-1B636BF3CCE6Q40993947-326BBFB6-8EE2-4C85-8946-058054F95BA9Q41109660-5C1FA6F9-CE93-4731-8532-B041DB8550D0Q42034393-9B133BA2-CF1F-4742-A7CF-6085E3493B29Q42152311-94F996AB-E38C-4235-9397-10876B21D623Q42989967-11B60483-D27C-45EB-9532-08C0C7CE551DQ43075860-D7694B14-B364-4CD6-A03F-3B6C853F8EFDQ43774226-94A75F48-55E4-411C-A13F-6CB77E77C4F3Q43897931-8F89D201-882C-4ACB-9C7F-7075C7EBBCE8Q44285397-B51BFD0F-6B18-4CAA-88A8-11DE58B4EA0EQ46483671-4ECDC4F9-C5B9-4554-9095-FFBAD873525F
P2860
The crystal structure of PR3, a neutrophil serine proteinase antigen of Wegener's granulomatosis antibodies
description
1996 nî lūn-bûn
@nan
1996 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
The crystal structure of PR3, ...... er's granulomatosis antibodies
@ast
The crystal structure of PR3, ...... er's granulomatosis antibodies
@en
The crystal structure of PR3, ...... er's granulomatosis antibodies
@nl
type
label
The crystal structure of PR3, ...... er's granulomatosis antibodies
@ast
The crystal structure of PR3, ...... er's granulomatosis antibodies
@en
The crystal structure of PR3, ...... er's granulomatosis antibodies
@nl
prefLabel
The crystal structure of PR3, ...... er's granulomatosis antibodies
@ast
The crystal structure of PR3, ...... er's granulomatosis antibodies
@en
The crystal structure of PR3, ...... er's granulomatosis antibodies
@nl
P2093
P356
P1476
The crystal structure of PR3, ...... er's granulomatosis antibodies
@en
P2093
M Fujinaga
M M Chernaia
R Halenbeck
P304
P356
10.1006/JMBI.1996.0458
P407
P577
1996-08-16T00:00:00Z